X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (63203) 63203
Newsletter (623) 623
Book Chapter (182) 182
Newspaper Article (76) 76
Dissertation (64) 64
Magazine Article (52) 52
Book / eBook (15) 15
Conference Proceeding (10) 10
Publication (8) 8
Reference (5) 5
Web Resource (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50200) 50200
female (36351) 36351
male (32253) 32253
middle aged (31919) 31919
aged (28213) 28213
oncology (26148) 26148
cancer (24201) 24201
adult (22338) 22338
prognosis (19769) 19769
carcinoma, squamous cell - mortality (13589) 13589
surgery (13260) 13260
squamous cell carcinoma (12662) 12662
aged, 80 and over (12402) 12402
neoplasm staging (12146) 12146
carcinoma (11960) 11960
carcinoma, squamous cell - pathology (11614) 11614
metastasis (10730) 10730
retrospective studies (10629) 10629
survival (10287) 10287
chemotherapy (10169) 10169
squamous-cell carcinoma (9891) 9891
tumors (9789) 9789
survival rate (9592) 9592
analysis (8579) 8579
care and treatment (8568) 8568
research (8486) 8486
expression (8002) 8002
treatment outcome (7876) 7876
carcinoma, squamous cell - surgery (7060) 7060
survival analysis (6945) 6945
lung cancer (6931) 6931
risk factors (6910) 6910
radiotherapy (6722) 6722
medical prognosis (6703) 6703
health aspects (6616) 6616
follow-up studies (6567) 6567
immunohistochemistry (6349) 6349
gene expression (5843) 5843
mortality (5712) 5712
lung neoplasms - pathology (5690) 5690
lung neoplasms - mortality (5576) 5576
esophageal cancer (5458) 5458
patients (5343) 5343
disease-free survival (5237) 5237
medicine & public health (5220) 5220
proteins (5210) 5210
apoptosis (5170) 5170
development and progression (4939) 4939
cancer therapies (4907) 4907
lymphatic metastasis (4878) 4878
adenocarcinoma (4853) 4853
pathology (4835) 4835
genetic aspects (4814) 4814
head (4586) 4586
diagnosis (4558) 4558
kaplan-meier estimate (4515) 4515
cell line, tumor (4474) 4474
carcinoma, squamous cell - therapy (4393) 4393
adenocarcinoma - mortality (4312) 4312
combined modality therapy (4304) 4304
otorhinolaryngology (4299) 4299
animals (4284) 4284
studies (4104) 4104
carcinoma, squamous cell - radiotherapy (3855) 3855
carcinoma, non-small-cell lung - pathology (3834) 3834
esophageal neoplasms - pathology (3814) 3814
carcinoma, non-small-cell lung - mortality (3784) 3784
metastases (3776) 3776
esophageal neoplasms - mortality (3736) 3736
adenocarcinoma - pathology (3720) 3720
lung cancer, non-small cell (3663) 3663
biomarkers (3652) 3652
gene expression regulation, neoplastic (3651) 3651
multivariate analysis (3637) 3637
research article (3549) 3549
medicine (3522) 3522
antineoplastic combined chemotherapy protocols - therapeutic use (3454) 3454
risk (3424) 3424
proportional hazards models (3312) 3312
time factors (3308) 3308
head and neck cancer (3248) 3248
breast-cancer (3244) 3244
hematology, oncology and palliative medicine (3232) 3232
cell biology (3202) 3202
carcinoma, squamous cell - genetics (3171) 3171
radiation therapy (3121) 3121
therapy (3115) 3115
oncology, experimental (3069) 3069
cell proliferation (3038) 3038
medicine, research & experimental (3005) 3005
medical research (2983) 2983
kinases (2964) 2964
cervical cancer (2937) 2937
head and neck neoplasms - mortality (2928) 2928
neoplasm invasiveness (2922) 2922
patient outcomes (2889) 2889
epidemiology (2876) 2876
respiratory system (2856) 2856
young adult (2843) 2843
carcinoma, squamous cell - drug therapy (2842) 2842
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (62314) 62314
German (681) 681
Japanese (526) 526
French (401) 401
Chinese (380) 380
Russian (216) 216
Spanish (179) 179
Portuguese (128) 128
Italian (127) 127
Polish (93) 93
Turkish (27) 27
Hungarian (19) 19
Norwegian (16) 16
Dutch (14) 14
Czech (12) 12
Hebrew (12) 12
Danish (11) 11
Korean (9) 9
Serbian (9) 9
Lithuanian (8) 8
Romanian (7) 7
Arabic (6) 6
Bulgarian (6) 6
Croatian (6) 6
Swedish (6) 6
Ukrainian (5) 5
Finnish (4) 4
Persian (4) 4
Icelandic (2) 2
Amharic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 2, pp. 123 - 135
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 21, pp. 2040 - 2051
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 9, pp. 1566 - 1575
BACKGROUND Human papillomavirus (HPV) is a well‐established prognostic marker for oropharyngeal squamous cell cancer (OPSCC... 
human papillomavirus (HPV) | head and neck squamous cell cancer (HNSCC) | p16 | race | sex | oropharyngeal squamous cell cancer (OPSCC) | prognosis | UNITED-STATES | POSITIVE HEAD | IN-SITU HYBRIDIZATION | IMPROVED SURVIVAL | TRIAL | NASOPHARYNGEAL CARCINOMA | HPV STATUS | THERAPY | ONCOLOGY | IMMUNOHISTOCHEMISTRY | Oropharyngeal Neoplasms - ethnology | Head and Neck Neoplasms - virology | Nasopharyngeal Neoplasms - mortality | Prognosis | Asian Americans - statistics & numerical data | Carcinoma, Squamous Cell - pathology | Carcinoma, Squamous Cell - virology | Humans | Nasopharyngeal Neoplasms - ethnology | Nasopharyngeal Neoplasms - virology | Oropharyngeal Neoplasms - mortality | Hispanic Americans - statistics & numerical data | Male | Oropharyngeal Neoplasms - pathology | Carcinoma, Squamous Cell - ethnology | Laryngeal Neoplasms - pathology | Nasopharyngeal Neoplasms - pathology | Mouth Neoplasms - ethnology | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - mortality | Head and Neck Neoplasms - ethnology | Laryngeal Neoplasms - ethnology | Female | Papillomavirus Infections - virology | Retrospective Studies | Repressor Proteins - metabolism | Oncogene Proteins, Viral - metabolism | Ethnic Groups - statistics & numerical data | Papillomavirus Infections - epidemiology | Proportional Hazards Models | European Continental Ancestry Group - statistics & numerical data | Oropharyngeal Neoplasms - virology | Mouth Neoplasms - virology | Mouth Neoplasms - mortality | Human papillomavirus 16 - metabolism | Head and Neck Neoplasms - pathology | African Americans - statistics & numerical data | Papillomavirus E7 Proteins - metabolism | Laryngeal Neoplasms - mortality | Sex Factors | Cyclin-Dependent Kinase Inhibitor p16 - metabolism | Mouth Neoplasms - pathology | Head and Neck Neoplasms - mortality | Neoplasm Staging | DNA, Viral | Human papillomavirus 16 - genetics | Laryngeal Neoplasms - virology | Complications and side effects | Care and treatment | DNA | Head and neck cancer | Research | Papillomavirus infections | Risk factors | Sex | Risk | Population studies | mRNA | Nasopharynx | Human papillomavirus | Race | Larynx | Deoxyribonucleic acid--DNA | Squamous cell carcinoma | Head | Adjustment | Mortality | Health risks | Hazards | Ribonucleic acid--RNA | Minority & ethnic groups | Patients | Survival | Oral cavity | Tobacco | Medical prognosis | Men | Health hazards | Health risk assessment | Hispanics | Cancer | Tumors
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer (NSCLC... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
PloS one, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0136023
.... First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors... 
CELL LUNG-CANCER | TUMOR-INFILTRATING LYMPHOCYTES | INTERLEUKIN-2 | GEFITINIB | IMPACT | MULTIDISCIPLINARY SCIENCES | ANTIBODY | B7-H1 | T-CELLS | CHEMOTHERAPY | LIGAND 1 EXPRESSION | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Carcinoma, Squamous Cell - mortality | Neoplasm Grading | Biomarkers, Tumor - metabolism | Female | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Carcinoma, Squamous Cell - therapy | Programmed Cell Death 1 Receptor - metabolism | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | B7-H1 Antigen - metabolism | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Care and treatment | Physiological aspects | Genetic aspects | Research | Lung cancer, Non-small cell | Apoptosis | Immunohistochemistry | Thoracic surgery | PD-1 protein | Lung cancer | Clinical trials | Oncology | Cancer therapies | Lymph nodes | Subgroups | Proteins | Rank tests | Regression models | Bcl-x protein | Lymphocytes | Immunotherapy | Medical research | Immunoglobulins | Squamous cell carcinoma | Cell survival | Cytokines | Hematology | Tumor cells | Non-small cell lung carcinoma | Breast cancer | Regression analysis | Patients | Medicine | Pathology | Chemotherapy | Hospitals | Cell death | Medical prognosis | PD-L1 protein | Ligands | Diagnostic systems | Solid tumors | Cancer | Tumors
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 697 - 710
Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SCCHN... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | P16 | ONCOLOGY | COLORECTAL-CANCER | OROPHARYNGEAL CANCER | HUMAN-PAPILLOMAVIRUS | P16(INK4A) | SUBSET | III TRIAL | COOPERATIVE-ONCOLOGY-GROUP | PLUS FLUOROURACIL | Immunohistochemistry | South America | Head and Neck Neoplasms - virology | Prospective Studies | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Neoplasm Recurrence, Local - virology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | North America | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Head and Neck Neoplasms - chemistry | Neoplasm Metastasis | Carcinoma, Squamous Cell - mortality | Cyclin-Dependent Kinase Inhibitor p16 - analysis | Fluorouracil - administration & dosage | Time Factors | Female | Retrospective Studies | Biomarkers, Tumor - analysis | Europe | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Squamous Cell - chemistry | Treatment Outcome | Papillomaviridae - isolation & purification | Neoplasm Recurrence, Local - chemistry | Head and Neck Neoplasms - pathology | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Biopsy | Carcinoma, Squamous Cell - secondary | Aged | Head and Neck Neoplasms - mortality | Care and treatment | Relapse | Carcinoma | Monoclonal antibodies | Product development | Metastasis | Cisplatin | Cancer | Diseases | Index Medicus
Journal Article